Hormone exposure and its suppressive effect on risk of high-grade gliomas among patients with breast cancer |
| |
| Affiliation: | 1. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA;2. Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA;3. Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA;4. Department of Pathology and Laboratory Medicine Northwestern, Chicago, IL, USA;5. Memorial Hermann Hospital, Houston, TX, USA;6. Center of Precision Health, School of Biomedical Informatics, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA;2. Department of Statistics and Modelling Science, University of Strathclyde, Glasgow, United Kingdom;3. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom;1. Department of Neurosurgery, K.E.M. Hospital and Seth G.S. Medical College, Parel, Mumbai, India;2. Department of Neurosurgery, Lilavati Hospital and Research Centre, Bandra, Mumbai, India;1. School of Medicine, University of Sinú, Cartagena, Colombia;2. School of Medicine, Rafael Núñez University Corporation, Cartagena, Colombia;3. Colombian Clinical Research Group in Neurocritical Care, School of Medicine, University of Cartagena, Cartagena, Colombia;4. Latin American Council of Neurocritical Care, Cartagena, Colombia;1. Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran;2. Neuroscience Research Center, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran;1. Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA;2. Department of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA;3. Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden;4. Department of Clinical Neuroscience and Department of Medicine, Karolinska Institutet, Stockholm, Sweden;5. Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark;6. Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA;1. Department of Neurology, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville TN 37232, USA;3. Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112, USA;4. Department of Communication Science and Disorders, University of Pittsburgh School of Health and Rehabilitation Sciences, 5035 Forbes Tower, Pittsburgh, PA 15260, USA;5. Department of Physical Medicine and Rehabilitation, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN 37232, USA |
| |
| Abstract: | BackgroundPrior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized.MethodsUsing the SEER 18 registries (2000–2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients.ResultsDuring the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma.ConclusionOur study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways. |
| |
| Keywords: | High-grade glioma Glioblastoma Breast cancer Hormone exposure Anaplastic astrocytoma SEER |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
